1. All Articles

    1-24 of 2902 1 2 3 4 ... 119 120 121 »
    1. Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

      Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

      Int J Radiat Oncol Biol Phys. 2018 Jan 09;:

      Authors: Casey DL, Pitter KL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL

      Read Full Article
    2. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      Mol Cancer Ther. 2018 Feb 13;:

      Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R

      Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.

      Read Full Article
    3. Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Oncol Rep. 2018 Feb 09;:

      Authors: Li C, Yang C, Wei G

      Abstract Resistance is the major cause of cisplatin treatment failure in neuroblastoma (NB). Vandetanib is widely used in the treatment of several cancers. In the present study, we aimed to determine the potential of vandetanib in cisplatin‑resistant NB therapy.

      Read Full Article
      Mentions: Treatment
    4. Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation.

      Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation.

      Pediatr Surg Int. 2018 Feb 08;:

      Authors: Hiramatsu T, Yoshizawa J, Miyaguni K, Sugihara T, Harada A, Kaji S, Uchida G, Kanamori D, Baba Y, Ashizuka S, Ohki T

      Read Full Article
      Mentions: Treatment
    5. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

      Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

      Oncotarget. 2018 Jan 05;9(2):2304-2319

      Authors: Arnhold V, Schmelz K, Proba J, Winkler A, Wünschel J, Toedling J, Deubzer HE, Künkele A, Eggert A, Schulte JH, Hundsdoerfer P

      Read Full Article
      Mentions: MYCN
    6. MELK is a novel therapeutic target in high-risk neuroblastoma.

      MELK is a novel therapeutic target in high-risk neuroblastoma.

      Oncotarget. 2018 Jan 05;9(2):2591-2602

      Authors: Guan S, Lu J, Zhao Y, Yu Y, Li H, Chen Z, Shi Z, Liang H, Wang M, Guo K, Chen X, Sun W, Bieerkehazhi S, Xu X, Sun S, Agarwal S, Yang J

      Abstract Maternal embryonic leucine zipper kinase (MELK) is known to modulate intracellular signaling and control cellular processes. However, the role of MELK in oncogenesis is not well defined.

      Read Full Article
      Mentions: MYCN
    7. Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site.

      Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site.

      Q J Nucl Med Mol Imaging. 2018 Feb 05;:

      Authors: Gauthé M, Breton M, Jehanno N, Cellier C, Michon J, Sarnacki S, Schleiermacher G, Wartski M

      Read Full Article
      Mentions: Surgery Imaging MYCN
    8. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.

      MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.

      Biochim Biophys Acta. 2018 Feb 02;:

      Authors: Ferrucci F, Ciaccio R, Monticelli S, Pigini P, di Giacomo S, Purgato S, Erriquez D, Bernardoni R, Norris M, Haber M, Milazzo G, Perini G

      Read Full Article
      Mentions: MYCN
    9. SPECT/CT Mibg Imaging Is Crucial in the Follow-up of the Patients With High-Risk Neuroblastoma.

      SPECT/CT MIBG Imaging Is Crucial in the Follow-up of the Patients With High-Risk Neuroblastoma.

      Clin Nucl Med. 2018 Feb 03;:

      Authors: Liu B, Servaes S, Zhuang H

      Abstract BACKGROUND: Planar whole-body imaging with I-radiolabeled metaiodobenzylguanidine (I-MIBG) is routinely used in the follow-up evaluation of neuroblastoma. In recent years, SPECT with integrated low-dose CT (SPECT/CT) has become more accessible.

      Read Full Article
      Mentions: Imaging MIBG
    10. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.

      Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.

      Int J Oncol. 2018 Jan 31;:

      Authors: Chen L, Esfandiari A, Reaves W, Vu A, Hogarty MD, Lunec J, Tweddle DA

      Abstract Cell lines established from the TH-MYCN transgenic murine model of neuroblastoma are a valuable preclinical, immunocompetent, syngeneic model of neuroblastoma, for which knowledge of their p53 pathway status is important.

      Read Full Article
      Mentions: MYCN
    11. A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

      A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

      Medicine (Baltimore). 2017 Dec;96(50):e8845

      Authors: Yuan LQ, Wang JH, Zhu K, Yang M, Gu WZ, Lai C, Li HM, Shu Q, Chen X

      Read Full Article
    12. Biological and Genetic Features of Neuroblastoma and Their Clinical Importance.

      Biological and Genetic Features of Neuroblastoma and Their Clinical Importance.

      Curr Pediatr Rev. 2018 Jan 28;:

      Authors: Aygun N

      Abstract Neuroblastoma derived from primitive cells of the sympathetic nervous system typically develops in the adrenal medulla or paraspinal ganglia. Neuroblastoma usually occurs sporadically, but familial cases are also observed.

      Read Full Article
      Mentions: ALK MYCN PHOX2B
    13. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

      Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

      Lancet Child Adolesc Health. 2018 Jan;2(1):25-34

      Authors: de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL

      Read Full Article
      Mentions: COG Chemotherapy
    14. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

      PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

      PLoS Med. 2018 Jan;15(1):e1002497

      Authors: Srinivasan P, Wu X, Basu M, Rossi C, Sandler AD

      Read Full Article
      Mentions: PD-1
    15. Estrogen causes neuroblastoma cells to mature into neurons

      The female sex hormone estrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers demonstrate that estrogen treatment and overexpression of the estrogen receptor cause malignant neuroblastoma cells to mature into neuron-like cells. The studygives hope of new treatment possibilities.

      Read Full Article
      Mentions: Treatment
    16. Inhibition of Sirtuin 6 Induces Neuroblastoma Differentiation.

      Inhibition of Sirtuin 6 Induces Neuroblastoma Differentiation.

      Anticancer Res. 2018 Feb;38(2):647-654

      Authors: Song HY, Rellinger EJ, Park SH, Paul P, Qiao J, Vasilopoulos A, Ozden O, Gius D, Chung DH

      Abstract BACKGROUND/AIM: Sirtuins (SIRTs) play crucial roles in various signaling pathways that modulate differentiation and proliferation. We sought to elucidate the role of SIRTs in differentiation and proliferation of human neuroblastoma (NB).

      Read Full Article
    17. The ALK receptor in sympathetic neuron development and neuroblastoma.

      The ALK receptor in sympathetic neuron development and neuroblastoma.

      Cell Tissue Res. 2018 Jan 27;:

      Authors: Janoueix-Lerosey I, Lopez-Delisle L, Delattre O, Rohrer H

      Abstract The ALK gene encodes a tyrosine kinase receptor characterized by an expression pattern mainly restricted to the developing central and peripheral nervous systems.

      Read Full Article
      Mentions: ALK
    18. Oestrogen causes neuroblastoma cells to mature into neurons

      Oestrogen causes neuroblastoma cells to mature into neurons

      ( Karolinska Institutet ) The female sex hormone oestrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers at Karolinska Institutet in Sweden demonstrate that oestrogen treatment and overexpression of the oestrogen receptor cause malignant neuroblastoma cells to mature into neuron-like cells. The study, which is published in PNAS, gives hope of new treatment possibilities.

      Read Full Article
      Mentions: Treatment MYCN
    1-24 of 2902 1 2 3 4 ... 119 120 121 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. INBRACED

    See all INBRACED articles
  4. Organizations in the News

    1. (87 articles) COG
    2. (25 articles) NANT
    3. (22 articles) SIOP
    4. (19 articles) SIOPEN
    5. (18 articles) MSKCC
    6. (15 articles) INRG
    7. (15 articles) GPOH
    8. (11 articles) NMTRC
  5. Locations in the News

    1. (9 articles) Other Countries
  6. Researches in the News

    1. (261 articles) MYCN
    2. (212 articles) Immunotherapy
    3. (140 articles) Antibody
    4. (118 articles) ALK
    5. (89 articles) Imaging
    6. (75 articles) T-Cells
    7. (62 articles) Bone Marrow
    8. (47 articles) Metastasis
    9. (46 articles) ASCO
    10. (32 articles) PD-1
  7. General Informations in the News

    1. (424 articles) Treatment
    2. (24 articles) Staging
    3. (6 articles) Hearing Loss
  8. Treatments in the News

    1. (104 articles) Surgery
    2. (92 articles) Chemotherapy
    3. (91 articles) Refractory
    4. (84 articles) MIBG
    5. (68 articles) Stem Cell Transplant
    6. (65 articles) Relapse
    7. (61 articles) Radiotherapy
    8. (21 articles) Side Effects
    9. (20 articles) Diagnostics
    10. (9 articles) Targetted Therapy